Investigational Drug Information for Epelsiban
✉ Email this page to a colleague
What is the drug development status for Epelsiban?
Epelsiban is an investigational drug.
There have been 4 clinical trials for Epelsiban.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.
The most common disease conditions in clinical trials are Adenomyosis and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].
There are twelve US patents protecting this investigational drug and one hundred and thirty-one international patents.
Summary for Epelsiban
| US Patents | 12 |
| International Patents | 131 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2016-07-01) |
| Vendors | 17 |
Recent Clinical Trials for Epelsiban
| Title | Sponsor | Phase |
|---|---|---|
| Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis | GlaxoSmithKline | Phase 2 |
| Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers | GlaxoSmithKline | Phase 1 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for Epelsiban
Top disease conditions for Epelsiban
Top clinical trial sponsors for Epelsiban
US Patents for Epelsiban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Epelsiban | ⤷ Sign Up | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | Ferring B.V. (Hoofddorp, NL) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (Hoofddorp, NL) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Piperazinediones as oxytocin receptor antagonists | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Compounds | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Compounds | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Sign Up |
| Epelsiban | ⤷ Sign Up | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-- (4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione | Glaxo Group Limited (Brentford, Middlesex, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Epelsiban
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Epelsiban | Australia | AU2015367900 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | Brazil | BR112017013521 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | Canada | CA2971846 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | Chile | CL2017001640 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | China | CN107249618 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | China | CN113940990 | 2034-12-22 | ⤷ Sign Up |
| Epelsiban | Eurasian Patent Organization | EA201791361 | 2034-12-22 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
